Effects of incorporation of 6-thioguanine into SV40 DNA. 1987

J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
Department of Pharmacology, Upjohn Center for Clinical Pharmacology, University of Michigan Medical School, Ann Arbor 48109.

The antileukemic agent 6-thioguanine (TG) is thought to inhibit DNA synthesis as a result of its incorporation into DNA. In the present study we have examined the nature of this inhibition, using replication of SV40 viral DNA as a model system. Addition of TG to SV40-infected CV1P cells from 22 to 24 hr post infection causes a dose-dependent inhibition of viral DNA synthesis. This inhibition plateaus between 250 and 2500 microM TG, resulting in a maximum decrease of viral DNA synthesis of about 50%. Pulse-chase experiments showed no detectable slowing of elongation of nascent DNA chains, whereas measurement of the conversion of incorporated 3H-dThd into supercoiled viral DNA suggested that elongation might be slightly inhibited, but by no more than 20%. Since inhibition of elongation could not account for the total depression of DNA synthesis, we hypothesized that inhibition of initiation of DNA replication takes place. This hypothesis was tested by radioactively labeling newly synthesized viral DNA and then assessing the ability of these molecules to reenter the replicating pool by density labeling with bromodeoxyuridine. The fraction of TG-containing molecules able to re-initiate replication was decreased 15%, compared to control. This effect, which was dependent on the concentration of TG added to the medium, was closely correlated to the extent of TG incorporation into the viral genome. We concluded that a portion of SV40 viral DNA synthesis inhibited by TG is due to an effect on initiation, and hypothesized that this effect may be caused by the substitution of TG for guanine in critical recognition sequences at the origin of replication. We proceeded to test this hypothesis by constructing SV40 origin sequences containing TG and then measuring their ability to bind T-antigen in vitro. The necessary deoxynucleoside triphosphate, TdGTP, was obtained by chemical phosphorylation of thiodeoxyguanosine. In order to selectively place TG within the desired region, a plasmid containing the T-antigen binding sequences was linearized so as to place these sequences at one end of the molecule, and then digested briefly with exonuclease III. The excised strand was resynthesized by use of the Klenow fragment of DNA polymerase I along with various nucleotide mixtures. Although resynthesis with mixtures containing TdGTP in place of dGTP was impeded somewhat, it was possible to achieve complete resynthesis with this analog.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013539 Simian virus 40 A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures. SV40 Virus,Vacuolating Agent,Polyomavirus macacae,SV 40 Virus,SV 40 Viruses,SV40 Viruses,Vacuolating Agents
D013866 Thioguanine An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. 6-Thioguanine,2-Amino-6-Purinethiol,Lanvis,Tabloid,Thioguanin-GSK,Thioguanine Anhydrous,Thioguanine Hemihydrate,Thioguanine Monosodium Salt,Thioguanine Tabloid,Tioguanina Wellcome,Tioguanine,2 Amino 6 Purinethiol,6 Thioguanine,Anhydrous, Thioguanine,Thioguanin GSK,ThioguaninGSK

Related Publications

J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
August 1997, Biochemical pharmacology,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
April 1960, Cancer research,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
November 1992, Molecular pharmacology,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
June 2017, Nucleosides, nucleotides & nucleic acids,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
September 1999, Journal of experimental & clinical cancer research : CR,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
April 1973, Virology,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
December 1977, Cancer research,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
June 2013, Journal of clinical pharmacology,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
March 1991, Molecular pharmacology,
J Maybaum, and A N Bainnson, and W M Roethel, and S Ajmera, and L M Iwaniec, and D R TerBush, and J J Kroll
April 1961, The Journal of biological chemistry,
Copied contents to your clipboard!